老年正常核型急性髓系白血病的临床特征及预后分析
发布时间:2018-09-01 13:32
【摘要】:研究背景急性髓系白血病(AML)是一种具有高度异质性的造血干细胞恶性克隆疾病。其中老年AML患者占总AML患者的50%以上,且发病率逐年提高。与年轻AML患者相比,老年AML患者有不同的生物学及临床特征,其预后差,与高龄、化疗耐受差、一般状况差、并发症多、更易有异常细胞遗传学等因素有关。细胞遗传学在AML的预后有十分重要的作用,根据NCCN指南,CN-AML(正常核型AML)归为预后中危组,但此类患者仍表现高度异质性,在初治的老年AML中,约有45-50%患者表现为正常核型(CN-AML)。老年CN-AML的临床及预后尚不明确,因此,对这类患者进行研究,有助于对其进行分层,为个体化治疗提供依据。研究目的回顾性分析104例老年CN-AML患者(年龄≥60岁)的临床特征及疗效,并分析影响其预后的相关因素。材料与方法回顾性分析2012年1月1日至2016年1月1日就诊于郑州大学第一附属医院的104例初发老年(≥60岁)CN-AML(非M3)患者的临床资料。其中M01例,M16例,M245例,M410例,M538例,M64例。原发AML患者88例,继发AML患者16例(均继发于骨髓增生异常综合症(MDS))。收集资料包括患者年龄、性别、初诊时临床症状、合并疾病、血常规、骨髓细胞学免疫分型、分子生物学改变、细胞遗传学改变以及诱导缓解情况等。免疫表型分析采用流式细胞术分析。急性髓系白血病预后基因突变检测采用PCR法,染色体分析采用G显带法,患者CCI评分根据Charlson合并指数。使用卡方检验分析完全缓解(CR)的影响因素。生存分析采用Kaplan-Mier生存曲线,并使用Log-rank检验对预后相关影响因素进行单因素分析,多因素分析采用COX回归模型。P值0.05为差异有统计学意义。结果1.104例初治老年CN-AML患者,男60例(57.7%),女44例(42.3%),中位年龄67岁(60-89岁),初诊时白细胞计数(WBC)12.50×109/L(0-285×109/L),血红蛋白(Hb)79g/L(35-139 g/L),血小板计数(Plt)36×109/L(3-397×109/L),中性粒细胞计数1×109/L(0-220×109/L),骨髓原始细胞≥50%者59例(56.7%),骨髓原始细胞50%者45例(43.3%)。CD34、CD38、CD7、CD19、CD56表达阳性率分别为47.1%、92.6%、16.8%、4.2%、7.4%。2.104例患者,首次化疗后达CR率为38.9%,总有效率(ORR)为55.6%;化疗2疗程达CR率为54.2%,ORR为56.9%。WBC100×109/L(P=0.02)、NPM1突变阳性(χ2=6.876,P=0.009)的患者的CR率较高。3.104例患者平均OS是12.5个月,中位OS是6.9个月。单因素分析显示年龄(≥70岁),继发AML,高白细胞计数(≥100×109/L),FLT3-ITD突变阳性,CD7阳性、达CR诱导疗程(2个)以及CCI评分≥2分的患者OS较短(P0.05)。多因素分析显示FLT3-ITD突变阳性(HR:7.61,95%CI:1.80-32.11,p=0.006)及达CR诱导疗程(2个)(HR:10.11,95%CI:2.38-43.03,p=0.002)是患者OS的独立预后因素。结论1.老年CN-AML患者的临床特征有发热、贫血、出血及淋巴结肿大、肝脾肿大、胸骨压痛。2.老年CN-AML患者预后是多种因素综合作用的结果,FLT3-ITD突变阳性、达CR诱导疗程(2个)是老年CN-AML患者OS的独立影响因素。
[Abstract]:Background Acute myeloid leukemia (AML) is a highly heterogeneous malignant clonal disease of hematopoietic stem cells. The middle and aged AML patients accounted for more than 50% of the total AML patients, and the incidence increased year by year. Compared with the young AML patients, the elderly patients with AML have different biological and clinical characteristics, and their prognosis is poor, which is related to the old age, poor tolerance to chemotherapy, poor general condition, more complications and more abnormal cytogenetics. Cytogenetics plays an important role in the prognosis of AML. According to the NCCN guidelines, CN-AML (normal karyotype AML) is classified as a prognostic risk group, but this group of patients is still highly heterogeneous. In the newly treated elderly AML, about 45-50% of the patients showed normal karyotype (CN-AML). The clinical and prognosis of elderly CN-AML is not clear. Therefore, the study of this kind of patients is helpful to stratify them and provide basis for individualized treatment. Objective to retrospectively analyze the clinical features and efficacy of 104 elderly patients with CN-AML (age 鈮,
本文编号:2217359
[Abstract]:Background Acute myeloid leukemia (AML) is a highly heterogeneous malignant clonal disease of hematopoietic stem cells. The middle and aged AML patients accounted for more than 50% of the total AML patients, and the incidence increased year by year. Compared with the young AML patients, the elderly patients with AML have different biological and clinical characteristics, and their prognosis is poor, which is related to the old age, poor tolerance to chemotherapy, poor general condition, more complications and more abnormal cytogenetics. Cytogenetics plays an important role in the prognosis of AML. According to the NCCN guidelines, CN-AML (normal karyotype AML) is classified as a prognostic risk group, but this group of patients is still highly heterogeneous. In the newly treated elderly AML, about 45-50% of the patients showed normal karyotype (CN-AML). The clinical and prognosis of elderly CN-AML is not clear. Therefore, the study of this kind of patients is helpful to stratify them and provide basis for individualized treatment. Objective to retrospectively analyze the clinical features and efficacy of 104 elderly patients with CN-AML (age 鈮,
本文编号:2217359
本文链接:https://www.wllwen.com/yixuelunwen/zlx/2217359.html